Cardiorenal Anemia syndrome presents a complex challenge, particularly in managing iron deficiency. Effective iron supplementation is crucial, with hepcidin playing a key role in iron homeostasis. Clinical trials show that next-generation IV iron products outperform oral iron in treating heart failure patients. Updated guidelines now recommend IV iron to improve patient quality of life, and ongoing research continues to explore its benefits in heart failure and chronic kidney disease.